Recent Updates
Recently added Catalysts

Electrofusion DC vaccine

Phase 1

Renal Cell Carcinoma | Monoclonal antibody | Oncology |Sanofi|Last Updated: Jan 23, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00625755A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell CarcinomaPHASE1 COMPLETED 40 — — Dec 1, 2002Feb 1, 2008Jan 23, 20261 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To assess the safety of 3 serial vaccinations with allogeneic DCs: autologous tumor-derived cells subjected to electrofusion in patients with AJCC stage IV RCC
screening/baseline, treatment period, follow-up and long-term follow-up
Secondary Endpoints
To determine if 3 serial vaccinations of allogeneic DCs: autologous tumor-derived cells subjected to electrofusion will induce a clinical response as assessed by tumor response and will induce an immune response.
screening/baseline, treatment period, follow-up and long-term follow-up
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
Electrofusion DC vaccineBIOLOGICALTo assess the safety and efficacy of vaccinations
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * The patient must be \_\> 18 years of age * The patient must be diagnosed with AJCC stage IV (primary or relasped) RCC * The patient must have a baseline Eastern Cooperative Oncology Group (ECOG) Clinical performance of 0-1 * The patient must have accessible tumor (minimum of 2...

Countries:United States
Unlock Eligibility Criteria